Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 676

1.

Proteomics advances for precision therapy in ovarian cancer.

Labrie M, Kendsersky ND, Ma H, Campbell L, Eng J, Chin K, Mills GB.

Expert Rev Proteomics. 2019 Sep 13:1-10. doi: 10.1080/14789450.2019.1666004. [Epub ahead of print]

PMID:
31512530
2.

Cyclic Multiplexed-Immunofluorescence (cmIF), a Highly Multiplexed Method for Single-Cell Analysis.

Eng J, Thibault G, Luoh SW, Gray JW, Chang YH, Chin K.

Methods Mol Biol. 2020;2055:521-562. doi: 10.1007/978-1-4939-9773-2_24.

PMID:
31502168
3.

Lifestyle habits associated with nocturnal urination frequency: The Nagahama study.

Tabara Y, Matsumoto T, Murase K, Setoh K, Kawaguchi T, Nagashima S, Funada S, Kosugi S, Hirai T, Nakayama T, Wakamura T, Chin K, Matsuda F; Nagahama study group.

Neurourol Urodyn. 2019 Sep 4. doi: 10.1002/nau.24156. [Epub ahead of print]

PMID:
31486144
4.

Association of weak hip abduction strength with nocturia in older women: The Nagahama study.

Tabara Y, Ikezoe T, Matsumoto T, Murase K, Setoh K, Funada S, Kawaguchi T, Nagashima S, Kosugi S, Hirai T, Nakayama T, Wakamura T, Chin K, Ichihashi N, Tsuboyama T, Matsuda F.

Geriatr Gerontol Int. 2019 Sep 1. doi: 10.1111/ggi.13761. [Epub ahead of print]

PMID:
31475427
5.

Effect of Protease Inhibitors in Healing of the Vaginal Wall.

Florian-Rodriguez M, Chin K, Hamner J, Acevedo J, Keller P, Word RA.

Sci Rep. 2019 Aug 26;9(1):12354. doi: 10.1038/s41598-019-48527-0.

6.

Differentiating Precapillary From Postcapillary Pulmonary Hypertension.

Naeije R, Chin K.

Circulation. 2019 Aug 27;140(9):712-714. doi: 10.1161/CIRCULATIONAHA.119.040295. Epub 2019 Aug 26. No abstract available.

PMID:
31449453
7.

Safety and efficacy of amrubicin monotherapy in patients with platinum-refractory metastatic neuroendocrine carcinoma of the gastrointestinal tract: a single cancer center retrospective study.

Kitagawa Y, Osumi H, Shinozaki E, Ota Y, Nakayama I, Suzuki T, Wakatsuki T, Ichimura T, Ogura M, Ooki A, Takahari D, Suenaga M, Chin K, Yamaguchi K.

Cancer Manag Res. 2019 Jun 25;11:5757-5764. doi: 10.2147/CMAR.S201048. eCollection 2019.

8.

Association between sleep disturbance and nocturnal blood pressure profiles by a linear mixed model analysis: the Nagahama study.

Matsumoto T, Tabara Y, Murase K, Setoh K, Kawaguchi T, Nagashima S, Kosugi S, Nakayama T, Wakamura T, Hirai T, Matsuda F, Chin K; Nagahama Study Group.

Sleep Med. 2019 Sep;61:104-109. doi: 10.1016/j.sleep.2019.01.049. Epub 2019 Mar 5.

PMID:
31402214
9.

Frequent nocturnal urination in older men is associated with arterial stiffness: The Nagahama study.

Tabara Y, Matsumoto T, Murase K, Setoh K, Kawaguchi T, Nagashima S, Kosugi S, Hirai T, Nakayama T, Wakamura T, Chin K, Matsuda F; and the Nagahama study group.

Hypertens Res. 2019 Aug 9. doi: 10.1038/s41440-019-0309-4. [Epub ahead of print]

PMID:
31399710
10.

A 3-Year Overall Survival Update From a Phase 2 Study of Chemoselection With DCF and Subsequent Conversion Surgery for Locally Advanced Unresectable Esophageal Cancer.

Yokota T, Kato K, Hamamoto Y, Tsubosa Y, Ogawa H, Ito Y, Hara H, Ura T, Kojima T, Chin K, Hironaka S, Kii T, Kojima Y, Akutsu Y, Matsushita H, Kawakami K, Mori K, Makiuchi T, Nagumo R, Kitagawa Y.

Ann Surg Oncol. 2019 Aug 2. doi: 10.1245/s10434-019-07654-8. [Epub ahead of print]

PMID:
31376034
11.

Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial.

Yoshikawa T, Muro K, Shitara K, Oh DY, Kang YK, Chung HC, Kudo T, Chin K, Kadowaki S, Hamamoto Y, Hironaka S, Yoshida K, Yen CJ, Omuro Y, Bai LY, Maeda K, Ozeki A, Yoshikawa R, Kitagawa Y.

JAMA Netw Open. 2019 Aug 2;2(8):e198243. doi: 10.1001/jamanetworkopen.2019.8243.

12.

Correlation between eosinophil count, its genetic background and body mass index: The Nagahama Study.

Sunadome H, Matsumoto H, Izuhara Y, Nagasaki T, Kanemitsu Y, Ishiyama Y, Morimoto C, Oguma T, Ito I, Murase K, Muro S, Kawaguchi T, Tabara Y, Chin K, Matsuda F, Hirai T.

Allergol Int. 2019 Jul 1. pii: S1323-8930(19)30080-2. doi: 10.1016/j.alit.2019.05.012. [Epub ahead of print]

13.

Innate αβ T Cells Mediate Antitumor Immunity by Orchestrating Immunogenic Macrophage Programming.

Hundeyin M, Kurz E, Mishra A, Rossi JAK, Liudahl SM, Leis KR, Mehrotra H, Kim M, Torres LE, Ogunsakin A, Link J, Sears RC, Sivagnanam S, Goecks J, Islam KMS, Dolgalev I, Savadkar S, Wang W, Aykut B, Leinwand J, Diskin B, Adam S, Israr M, Gelas M, Lish J, Chin K, Farooq MS, Wadowski B, Wu J, Shah S, Adeegbe DO, Pushalkar S, Vasudevaraja V, Saxena D, Wong KK, Coussens LM, Miller G.

Cancer Discov. 2019 Sep;9(9):1288-1305. doi: 10.1158/2159-8290.CD-19-0161. Epub 2019 Jul 2.

PMID:
31266770
14.

Sex differences in the safety of S-1 plus oxaliplatin and S-1 plus cisplatin for patients with metastatic gastric cancer.

Yamada Y, Koizumi W, Nishikawa K, Gotoh M, Fuse N, Sugimoto N, Nishina T, Amagai K, Chin K, Niwa Y, Tsuji A, Imamura H, Tsuda M, Yasui H, Fujii H, Yamaguchi K, Yasui H, Hironaka S, Shimada K, Hyodo I.

Cancer Sci. 2019 Sep;110(9):2875-2883. doi: 10.1111/cas.14117. Epub 2019 Jul 23.

15.

Olfactomedin 4 downregulation is associated with tumor initiation, growth and progression in human prostate cancer.

Li H, Kim C, Liu W, Zhu J, Chin K, Rodriguez-Canales J, Rodgers GP.

Int J Cancer. 2019 Jun 26. doi: 10.1002/ijc.32535. [Epub ahead of print]

PMID:
31241767
16.

Systemic chemotherapy for gastric cancer with early recurrence after adjuvant S-1 monotherapy: a multicenter retrospective study.

Mitani S, Kadowaki S, Hasegawa H, Wakatsuki T, Hara H, Tajika M, Nishikawa K, Hirao M, Takahari D, Chin K, Muro K.

Int J Clin Oncol. 2019 Oct;24(10):1197-1203. doi: 10.1007/s10147-019-01477-z. Epub 2019 May 31.

PMID:
31152323
17.

Multicenter phase II study of trastuzumab with S-1 plus oxaliplatin for chemotherapy-naïve, HER2-positive advanced gastric cancer.

Takahari D, Chin K, Ishizuka N, Takashima A, Minashi K, Kadowaki S, Nishina T, Nakajima TE, Amagai K, Machida N, Goto M, Taku K, Wakatsuki T, Shoji H, Hironaka S, Boku N, Yamaguchi K.

Gastric Cancer. 2019 May 17. doi: 10.1007/s10120-019-00973-5. [Epub ahead of print]

PMID:
31102009
18.

Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial.

Yamada Y, Boku N, Mizusawa J, Iwasa S, Kadowaki S, Nakayama N, Azuma M, Sakamoto T, Shitara K, Tamura T, Chin K, Hata H, Nakamori M, Hara H, Yasui H, Katayama H, Fukuda H, Yoshikawa T, Sasako M, Terashima M.

Lancet Gastroenterol Hepatol. 2019 Jul;4(7):501-510. doi: 10.1016/S2468-1253(19)30083-4. Epub 2019 May 14.

PMID:
31101534
19.

Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer.

Satoh T, Kang YK, Chao Y, Ryu MH, Kato K, Cheol Chung H, Chen JS, Muro K, Ki Kang W, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Tanimoto M, Chen LT, Boku N.

Gastric Cancer. 2019 May 13. doi: 10.1007/s10120-019-00970-8. [Epub ahead of print]

PMID:
31087200
20.

Second-line FOLFIRI plus ramucirumab with or without prior bevacizumab for patients with metastatic colorectal cancer.

Suzuki T, Shinozaki E, Osumi H, Nakayama I, Ota Y, Ichimura T, Ogura M, Wakatsuki T, Ooki A, Takahari D, Suenaga M, Chin K, Yamaguchi K.

Cancer Chemother Pharmacol. 2019 Aug;84(2):307-313. doi: 10.1007/s00280-019-03855-w. Epub 2019 May 7.

PMID:
31065729

Supplemental Content

Loading ...
Support Center